# A Study to Determine the Absorption, Metabolism, and Routes of Excretion of (14C) Radiolabeled Ibrutinib in Healthy Male Participants

> **NCT01674322** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 6 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** Ibrutinib

## Key facts

- **NCT ID:** NCT01674322
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2014-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01674322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01674322, "A Study to Determine the Absorption, Metabolism, and Routes of Excretion of (14C) Radiolabeled Ibrutinib in Healthy Male Participants". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01674322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*